ACADIA Pharmaceuticals (ACAD) vs Celcuity (CELC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Celcuity (CELC) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 33.4% versus a loss of 8.8%. Over five years, CELC leads with a +260.8% price change compared with +12.2% for ACAD. ACADIA Pharmaceuticals is the larger company by market cap ($3.39 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | CELC |
|---|---|---|
| Share price | $19.65 | $65.78 |
| Market cap | $3.39B | $3.22B |
| 1-day change | -0.46% | -7.68% |
| YTD return | -26.43% | -34.16% |
| 1-year return | -8.77% | +33.43% |
| 5-year return | +12.22% | +260.82% |
| P/E ratio (TTM) | 8.81 | — |
| Forward P/E | 22.12 | — |
| EPS (TTM) | $2.23 | $-4.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.96 | $151.02 |
| 52-week low | $19.46 | $45.03 |
| Distance from 52-week high | -36.53% | -56.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +63.66% | +138.54% |
| Average volume | 1.84M | 1.19M |
| Shares outstanding | 172.31M | 48.93M |
| Employees | 796 | 155 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELC has outperformed ACAD by 42.2 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
ACAD vs CELC FAQ
Which is bigger, ACADIA Pharmaceuticals or Celcuity?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $3.39B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, ACAD or CELC?
CELC returned +33.43% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Celcuity in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ACADIA Pharmaceuticals and Medical Specialities for Celcuity.